Medco: Follow-on biotech drugs could drive market growth

11/23/2008 | Reuters

Medco Health Solutions told investors Friday that follow-on biotech medicines could help the company and its customers save money if a regulatory pathway for such products is created. Assuming that an approval process would start in 2011, Amgen's Aranesp, Genentech's Avastin and Johnson & Johnson's Remicade would be among top-selling drugs that may face follow-on competition between 2013 and 2017, Medco said.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Catheter Engineer Manager
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD